Skip to main content
Equibles

4527 · ROHTO PHARMACEUTICAL CO.,LTD. · Financials

Use 4527 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4527.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
2,686.5 JPY +57.5 (+2.19%) At close · Nov 12
Rebalance outlook locked
Market Cap
604.26B JPY
Shares
224.93M
Volume · Nov 12 1.43M Avg daily vol (3M) 1.14M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
343.73B +11.4%
FY2026 Revenue FY2022–FY2026
Net Income
34.25B +10.5%
FY2026 Net Income FY2022–FY2026
Gross Margin
56.06% -0.6pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
11.96% -0.7pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
47.79B +29.4%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 343.73B 308.63B 270.84B 238.66B 199.65B
JPY 151.03B 133.69B 113.55B 101.24B 83.16B
JPY 192.7B 174.94B 157.29B 137.42B 116.49B
JPY 41.12B 38.94B 40.05B 33.96B 29.35B
JPY 46.82B 42.33B 41.52B 34.29B 27.95B
JPY 12.4B 11.38B 10.12B 7.86B 6.8B
JPY 34.25B 31.01B 30.94B 26.38B 21.02B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 29.91B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.